Nuvation Bio (NYSE:NUVB) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.11) by 9.09 percent. This is a 16.67 percent increase over losses of $(0.12) per share from the same period last year.
Canaccord Genuity Initiates Coverage On ForgeRock with Buy Rating, Announces Price Target of $20
Canaccord Genuity analyst Michael Walkley initiates coverage on ForgeRock (NYSE:FORG) with a Buy rating and announces Price Target of $20.